Section Arrow
PRPO.NASDAQ
- Precipio
Quotes are at least 15-min delayed:2026/01/12 17:04 EST
After Hours
Last
 25.7
-0.3599 (-1.38%)
Bid
24.21
Ask
25.9
High 25.7 
Low 25.7 
Volume
Regular Hours (Closed)
Last
 26.0599
+1.2899 (+5.21%)
Day High 
26.0599 
Prev. Close
24.77 
1-M High
26 
Volume 
4.82K 
Bid
24.21
Ask
25.9
Day Low
24.225 
Open
24.59 
1-M Low
22.1 
Market Cap 
43.40M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 23.5 
20-SMA 23.63 
50-SMA 22.9 
52-W High 28.5 
52-W Low 3.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.81/0.39
Enterprise Value
44.03M
Balance Sheet
Book Value Per Share
7.85
Cash Flow
Cash Flow Yield
0.02
Income Statement
Total Revenue
18.53M
Operating Revenue Per Share
6.25
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
BDSXBiodesix Inc8.08+2.62+47.99%-- 
After Hours 7.71 -0.37 -4.58%
NEOGNeogen Corp9.37-0.25-2.60%879PE
After Hours 9.49 +0.12 +1.28%
DHRDanaher Corp239+0.63+0.26%49.05PE
After Hours 240 +1 +0.42%
NEONeoGenomics12.49-0.67-5.09%-- 
After Hours 12.49 0 0.00%
TMOThermo Fisher Scientific615.45-3.41-0.55%35.75PE
After Hours 615.2016 -0.2484 -0.04%
Industry overview quotes are at least 15 minutes delayed
Business Description
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.